John G Ullman & Associates Inc. Reduces Stake in Moderna, Inc. (NASDAQ:MRNA)

John G Ullman & Associates Inc. trimmed its stake in Moderna, Inc. (NASDAQ:MRNA) by 91.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,650 shares of the company’s stock after selling 37,949 shares during the quarter. John G Ullman & Associates Inc.’s holdings in Moderna were worth $363,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Moderna during the 4th quarter valued at approximately $628,359,000. Renaissance Technologies LLC lifted its stake in shares of Moderna by 108.2% during the 1st quarter. Renaissance Technologies LLC now owns 3,818,180 shares of the company’s stock valued at $657,720,000 after buying an additional 1,984,458 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Moderna by 77.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock valued at $400,367,000 after buying an additional 1,690,341 shares in the last quarter. Morgan Stanley lifted its stake in shares of Moderna by 19.1% during the 4th quarter. Morgan Stanley now owns 4,187,353 shares of the company’s stock valued at $752,133,000 after buying an additional 670,284 shares in the last quarter. Finally, Invesco Ltd. lifted its stake in Moderna by 19.8% in the 3rd quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock worth $322,887,000 after purchasing an additional 517,683 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on MRNA. Canaccord Genuity Group raised their price target on shares of Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a report on Friday, February 23rd. Jefferies Financial Group reissued a “buy” rating and issued a $125.00 price target on shares of Moderna in a report on Tuesday, April 9th. HSBC reissued a “reduce” rating and issued a $86.00 price target (up from $75.00) on shares of Moderna in a report on Monday, February 26th. Oppenheimer raised shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price objective for the company in a report on Tuesday, January 2nd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a report on Thursday, April 11th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Moderna currently has a consensus rating of “Hold” and an average price target of $126.49.

Insider Activity

In related news, President Stephen Hoge sold 2,388 shares of the stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $225,833.16. Following the transaction, the president now owns 1,515,898 shares in the company, valued at $143,358,473.86. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $103.38, for a total transaction of $1,550,700.00. Following the completion of the transaction, the director now directly owns 2,056,931 shares of the company’s stock, valued at $212,645,526.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Stephen Hoge sold 2,388 shares of the firm’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $225,833.16. Following the transaction, the president now directly owns 1,515,898 shares of the company’s stock, valued at $143,358,473.86. The disclosure for this sale can be found here. Insiders have sold a total of 109,954 shares of company stock worth $11,533,976 over the last 90 days. 15.70% of the stock is currently owned by insiders.

Moderna Trading Down 0.6 %

NASDAQ:MRNA opened at $101.41 on Friday. Moderna, Inc. has a one year low of $62.55 and a one year high of $144.43. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 3.36. The company’s 50-day simple moving average is $100.63 and its 200 day simple moving average is $93.64.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, topping the consensus estimate of ($0.78) by $1.33. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The business had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.53 billion. During the same quarter in the previous year, the firm posted $3.61 earnings per share. Moderna’s quarterly revenue was down 44.9% on a year-over-year basis. As a group, equities analysts anticipate that Moderna, Inc. will post -7.51 earnings per share for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.